Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells 3,777 Shares of Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CFO Keith A. Goldan sold 3,777 shares of the firm's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the sale, the chief financial officer now directly owns 90,746 shares of the company's stock, valued at $1,406,563. This trade represents a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Syndax Pharmaceuticals Trading Down 1.1 %

Syndax Pharmaceuticals stock traded down $0.16 during midday trading on Friday, reaching $14.92. 1,304,942 shares of the stock traded hands, compared to its average volume of 2,238,445. The company has a 50-day simple moving average of $13.88 and a two-hundred day simple moving average of $17.11. Syndax Pharmaceuticals, Inc. has a 12-month low of $12.06 and a 12-month high of $25.34. The firm has a market cap of $1.27 billion, a PE ratio of -4.11 and a beta of 0.90.

Analysts Set New Price Targets

A number of brokerages have issued reports on SNDX. JPMorgan Chase & Co. raised their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an "overweight" rating in a research note on Thursday, November 21st. UBS Group initiated coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a "buy" rating and a $37.00 target price for the company. The Goldman Sachs Group increased their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Scotiabank lowered their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $36.20.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. R Squared Ltd acquired a new stake in Syndax Pharmaceuticals in the 4th quarter valued at about $26,000. Values First Advisors Inc. acquired a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at about $30,000. Quantbot Technologies LP acquired a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at about $49,000. Mirae Asset Global Investments Co. Ltd. raised its position in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock valued at $58,000 after purchasing an additional 541 shares in the last quarter. Finally, Virtus ETF Advisers LLC raised its position in Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after purchasing an additional 827 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).